Ose Immunotherapeutics annual net debt
2020
2021
2022
2023
2024
2025
Ose Immunotherapeutics Net Debt Growth & History (OSE)
Ose Immunotherapeutics's net debt was €17.8M for fiscal 2025.
View full Ose Immunotherapeutics company overviewOse Immunotherapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €17.8M | −€11.6M | −39.35% |
| 2024 | 2024-12-31 | €29.4M | €2.3M | +8.32% |
| 2023 | 2023-12-31 | €27.1M | €8.0M | +41.50% |
| 2022 | 2022-12-31 | €19.2M | €15.6M | +439.48% |
| 2021 | 2021-12-31 | €3.6M | €13.4M | — |
| 2020 | 2020-12-31 | −€9.9M | — | — |
Ose Immunotherapeutics quarterly net debt
Q4.24
Q4.25
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | €17.8M | −€11.6M | −39.35% |
| Q4 2024 | 2024-12-31 | €29.4M | — | — |
Ose Immunotherapeutics net debt trends
Over the last five fiscal years, Ose Immunotherapeutics's net debt increased from −€9.9M to €17.8M, a change of €27.7M. The latest reported quarter, Q4 2025, shows €17.8M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ose Immunotherapeutics source filings ↗